Literature DB >> 25175440

Staged-volume radiosurgery for large arteriovenous malformations: a review.

Kenan AlKhalili1, Nohra Chalouhi, Stavropoula Tjoumakaris, Robert Rosenwasser, Pascal Jabbour.   

Abstract

Stereotactic radiosurgery is an effective management strategy for properly selected patients with arteriovenous malformations (AVMs). However, the risk of postradiosurgical radiation-related injury is higher in patients with large AVMs. Multistaged volumetric management of large AVMs was undertaken to limit the radiation exposure to the surrounding normal brain. This strategy offers a promising method for obtaining high AVM obliteration rates with minimal normal tissue damage. The use of embolization as an adjunctive method in the treatment of large AVMs remains controversial. Unfortunately, staged-volume radiosurgery (SVR) has a number of potential pitfalls that affect the outcome. The aim of this article is to highlight the role of SVR in the treatment of large AVMs, to discuss the outcome comparing it to other treatment modalities, and to discuss the potential improvement that could be introduced to this method of treatment.

Entities:  

Keywords:  AVM = arteriovenous malformation; GKS = Gamma Knife surgery; LINAC = linear accelerator; SRS = stereotactic radiosurgery; SVR = staged-volume radiosurgery; Spetzler-Martin Grade; arteriovenous malformation; embolization; staged volume; stereotactic radiosurgery

Mesh:

Year:  2014        PMID: 25175440     DOI: 10.3171/2014.6.FOCUS14217

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  2 in total

1.  Utilization of hypofractionated radiotherapy in treatment of glioblastoma multiforme in elderly patients not receiving adjuvant chemoradiotherapy: A National Cancer Database Analysis.

Authors:  Brian Bingham; Chirayu G Patel; Eric T Shinohara; Albert Attia
Journal:  J Neurooncol       Date:  2017-12-05       Impact factor: 4.130

2.  Acute management of brain arteriovenous malformations.

Authors:  Andreas Hartmann; J P Mohr
Journal:  Curr Treat Options Neurol       Date:  2015-05       Impact factor: 3.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.